Project
Offene, nicht kontrollierte, multizentrische Phase IIIb Studie zur Beurteilung von Riociguat (BAY 63-2521) bei Patienten mit Chronisch Thromboembolischer Pulmonaler Hypertonie (CTEPH)
Aborted ยท 2013 until 2015
Brutsche Martin, Pellet Sarah, Finger Rebekka
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Aborted
Start Date
2013
End Date
2015
Financing
Industry
Study Design
The study will be conducted as an open-label, uncontrolled long-term
surveillance study to assess safety, tolerability, and clinical effects while providing early access of riociguat to patients with inoperable CTEPH, or recurrent or persisting PH after surgical treatment that are
not satisfactorily treated and cannot participate in any other CTEPH trial.
Brief description/objective
Objective
1) To assess safety and tolerability, clinical effects of riociguat.
2) To provide access to riociguat for patients with in-operable chronic
thromboembolic pulmonary hypertension (CTEPH), or recurrent or persisting pulmonary hypertension (PH) after surgical treatment who are not satisfactorily treated an d cannot participate in any other CTEPH trial.